1887

Abstract

A panel of human sera exhibited a ≥128-fold higher neutralizing potency against a human cytomegalovirus (HCMV) clinical isolate propagated and tested in endothelial (or epithelial) cells than against the same virus infecting human fibroblasts. In a group of 18 primary infections, the reverse geometric mean titre was in the range of 10–15 in human fibroblasts within the first 3 months after the onset of infection, whereas the endothelial cell infection-neutralizing activity was already present within the first 10 days, reaching median levels of 122, 320 and 545 at respectively 30, 60 and 90 days after onset, then declining slowly. This difference was also confirmed in the majority of reactivated and remote HCMV infections, as well as in a hyperimmune globulin preparation. The antibody response to HCMV pUL131A, pUL130 and pUL128 locus products, which are required for endothelial/epithelial cell infection, provided a potential molecular basis for such a differential neutralizing activity. In addition, monoclonal/monospecific antibodies raised against the pUL131A, pUL130 and pUL128 proteins were found to display an inhibitory activity on HCMV plaque formation and HCMV leukocyte transfer from HCMV-infected cells. Hence, conventional determination of the neutralizing activity of human sera in fibroblasts is misleading. Antibodies to pUL131A, pUL130 and pUL128 appear to display a major HCMV-neutralizing and dissemination-inhibiting activity.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83523-0
2008-04-01
2019-11-13
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/4/853.html?itemId=/content/journal/jgv/10.1099/vir.0.83523-0&mimeType=html&fmt=ahah

References

  1. Adler, B., Scrivano, L., Ruzcics, Z., Rupp, B., Sinzger, C. & Koszinowski, U. H. ( 2006; ). Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol 87, 2451–2460.[CrossRef]
    [Google Scholar]
  2. Andreoni, K. A., Wang, X., Huong, S.-M. & Huang, E.-S. ( 2001; ). Human cytomegalovirus CMV-IGIV (CytoGam®) neutralizes human cytomegalovirus (HCMV) infectivity and prevents intracellular signal transduction after HCMV exposure. Transplant Infect Dis 3, 25–30.[CrossRef]
    [Google Scholar]
  3. Bass, E. B., Powe, N. R., Goodman, S. N., Graziano, S. L., Griffiths, R. I., Kickler, T. S. & Wingard, J. R. ( 1993; ). Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 12, 273–282.
    [Google Scholar]
  4. Boeckh, M., Bowden, R. A., Storer, B., Chao, N. J., Spielberger, R., Tierney, D. K., Gallez-Hawkins, G., Cunningham, T., Blume, K. G. & other authors ( 2001; ). Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7, 343–351.[CrossRef]
    [Google Scholar]
  5. Eggers, M., Metzger, C. & Enders, G. ( 1998; ). Differentiation between acute primary and recurrent human cytomegalovirus infection in pregnancy, using a microneutralization assay. J Med Virol 56, 351–358.[CrossRef]
    [Google Scholar]
  6. Eggers, M., Bäder, U. & Enders, G. ( 2000; ). Combination of microneutralization and avidity assays: improved diagnosis of recent primary HCMV infection in single serum sample of second trimester pregnancy. J Med Virol 60, 324–330.[CrossRef]
    [Google Scholar]
  7. Eggers, M., Radsak, K., Enders, G. & Reschke, M. ( 2001; ). Use of recombinant antigens gB and gH for diagnosis of primary human cytomegalovirus infection during pregnancy. J Med Virol 63, 135–142.[CrossRef]
    [Google Scholar]
  8. Fowler, K. B., Stagno, S. & Pass, R. F. ( 2003; ). Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289, 1008–1011.[CrossRef]
    [Google Scholar]
  9. Gerna, G., Revello, M. G., Percivalle, E., Zavattoni, M., Parea, M. & Battaglia, M. ( 1990; ). Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins. J Clin Microbiol 28, 2681–2688.
    [Google Scholar]
  10. Gerna, G., Revello, M. G., Percivalle, E. & Morini, F. ( 1992; ). Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 30, 1232–1237.
    [Google Scholar]
  11. Gerna, G., Zavattoni, M., Baldanti, F., Sarasini, A., Chezzi, L., Grossi, P. & Revello, M. G. ( 1998; ). Human cytomegalovirus leukoDNAemia correlates more closely with clinical symptoms than antigenemia and viremia in heart and heart-lung transplant recipients with primary HCMV infection. Transplantation 65, 1378–1385.[CrossRef]
    [Google Scholar]
  12. Gerna, G., Percivalle, E., Baldanti, F., Sozzani, S., Lanzarini, P., Genini, E., Lilleri, D. & Revello, M. G. ( 2000; ). Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J Virol 74, 5629–5638.[CrossRef]
    [Google Scholar]
  13. Gerna, G., Percivalle, E., Sarasini, A., Baldanti, F., Campanini, G. & Revello, M. G. ( 2003; ). Rescue of human cytomegalovirus strain AD169 tropism for both leukocytes and human endothelial cells. J Gen Virol 84, 1431–1436.[CrossRef]
    [Google Scholar]
  14. Gerna, G., Percivalle, E., Lilleri, D., Lozza, L., Fornara, C., Hahn, G., Baldanti, F. & Revello, M. G. ( 2005; ). Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131–128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol 86, 275–284.[CrossRef]
    [Google Scholar]
  15. Gerna, G., Lilleri, D., Fornara, C., Comolli, G., Lozza, L., Campana, C., Pellegrini, C., Meloni, F. & Rampino, T. ( 2006a; ). Monitoring of human cytomegalovirus specific CD4+ and CD8+ T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 6, 2356–2364.[CrossRef]
    [Google Scholar]
  16. Gerna, G., Sarasini, A., Genini, E., Percivalle, E. & Revello, M. G. ( 2006b; ). Prediction of endothelial cell tropism of human cytomegalovirus strains. J Clin Virol 35, 470–473.[CrossRef]
    [Google Scholar]
  17. Gianni, T., Forghieri, C. & Campadelli-Fiume, G. ( 2006; ). The herpesvirus glycoproteins B and H.L are sequentially recruited to the receptor-bound gD to effect membrane fusion at virus entry. Proc Natl Acad Sci U S A 103, 14572–14577.[CrossRef]
    [Google Scholar]
  18. Grossi, P., Minoli, L., Percivalle, E., Irish, W., Vigano, M. & Gerna, G. ( 1995; ). Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 59, 847–851.[CrossRef]
    [Google Scholar]
  19. Hahn, G., Khan, A., Baldanti, F., Koszinowski, U. H., Revello, M. G. & Gerna, G. ( 2002; ). The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human cytomegalovirus with preserved wild-type characteristics. J Virol 76, 9551–9555.[CrossRef]
    [Google Scholar]
  20. Hahn, G., Revello, M. G., Patrone, M., Percivalle, E., Campanini, G., Sarasini, A., Wagner, M., Gallina, A., Milanesi, G. & other authors ( 2004; ). Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78, 10023–10033.[CrossRef]
    [Google Scholar]
  21. Lilleri, D., Gerna, G., Fornara, C., Lozza, L., Maccario, R. & Locatelli, F. ( 2006; ). Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 108, 1406–1412.[CrossRef]
    [Google Scholar]
  22. Messori, A., Rampazzo, R., Scroccaro, G. & Martini, N. ( 1994; ). Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation. A meta-analysis. Bone Marrow Transplant 13, 163–167.
    [Google Scholar]
  23. Muñoz, I., Gutiérrez, A., Gimeno, C., Farga, A., Alberola, J., Solano, C., Prósper, F., García-Conde, J. & Navarro, D. ( 2001; ). Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)-specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant. J Med Virol 65, 77–84.[CrossRef]
    [Google Scholar]
  24. Nigro, G., Adler, S. P., La Torre, R. & Best, A. M., Congenital Cytomegalovirus Collaborating Group ( 2005; ). Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353, 1350–1362.[CrossRef]
    [Google Scholar]
  25. Patrone, M., Secchi, M., Fiorina, L., Ierardi, M., Milanesi, G. & Gallina, A. ( 2005; ). Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion. J Virol 79, 8361–8373.[CrossRef]
    [Google Scholar]
  26. Patrone, M., Secchi, M., Bonaparte, E., Milanesi, G. & Gallina, A. ( 2007; ). Cytomegalovirus UL131–128 products promote gB conformational transition and gB-gH interaction during entry into endothelial cells. J Virol 81, 11479–11488.[CrossRef]
    [Google Scholar]
  27. Quinnan, G. V., Jr, Kirmani, N., Rook, A. H., Manischewitz, J. F., Jackson, L., Moreschi, G., Santos, G. W., Saral, R. & Burns, W. H. ( 1982; ). Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Engl J Med 307, 7–13.[CrossRef]
    [Google Scholar]
  28. Reusser, P., Riddel, S. R., Meyers, J. D. & Greenberg, P. D. ( 1991; ). Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78, 1373–1380.
    [Google Scholar]
  29. Revello, M. G. & Gerna, G. ( 2002; ). Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 15, 680–715.[CrossRef]
    [Google Scholar]
  30. Revello, M. G., Percivalle, E., Arbustini, E., Pardi, R., Sozzani, S. & Gerna, G. ( 1998; ). In vitro generation of human cytomegalovirus pp65 antigenemia, viremia, and leukoDNAemia. J Clin Invest 101, 2686–2692.[CrossRef]
    [Google Scholar]
  31. Revello, M. G., Baldanti, F., Percivalle, E., Sarasini, A., De-Giuli, L., Genini, E., Lilleri, D., Labò, N. & Gerna, G. ( 2001; ). In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells. J Gen Virol 82, 1429–1438.
    [Google Scholar]
  32. Ryckman, B. J., Rainish, B. L., Chase, M. C., Borton, J. A., Nelson, J. A., Jarvis, M. A. & Johnson, D. C. ( 2008; ). Characterization of the human cytomegalovirus gH/gL/UL128–131 complex that mediates entry into epithelial and endothelial cells. J Virol 82, 60–70.[CrossRef]
    [Google Scholar]
  33. Schoppel, K., Schmidt, C., Einsele, H., Hebart, H. & Mach, M. ( 1998; ). Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J Infect Dis 178, 1233–1243.[CrossRef]
    [Google Scholar]
  34. Sester, U., Gartner, B. C., Wilkens, H., Schwaab, B., Wossner, R., Kindermann, I., Girndt, M., Meyerhans, A., Mueller-Lantzsch, N. & other authors ( 2005; ). Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 5, 1483–1489.[CrossRef]
    [Google Scholar]
  35. Smith, M. G. ( 1956; ). Propagation in tissue cultures of cytopathogenic virus from human salivary gland virus (SGV) disease. Proc Soc Exp Biol Med 92, 424–430.[CrossRef]
    [Google Scholar]
  36. Stagno, S., Pass, R. F., Cloud, G., Britt, W. J., Henderson, R. E., Walton, P. D., Veren, D. A., Page, F. & Alford, C. A. ( 1986; ). Primary cytomegalovirus infection in pregnancy. Incidence, transmission to the fetus and clinical outcome. JAMA 256, 1904–1908.[CrossRef]
    [Google Scholar]
  37. Subramanian, R. P. & Geraghty, R. J. ( 2007; ). Herpes simplex virus type 1 mediates fusion through a hemifusion intermediate by sequential activity of glycoproteins D, H, L, and B. Proc Natl Acad Sci U S A 104, 2903–2908.[CrossRef]
    [Google Scholar]
  38. Wang, D. & Shenk, T. ( 2005a; ). Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 79, 10330–10338.[CrossRef]
    [Google Scholar]
  39. Wang, D. & Shenk, T. ( 2005b; ). Human cytomegalovirus virion protein complex required for endothelial and epithelial cell tropism. Proc Natl Acad Sci U S A 102, 18153–18158.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83523-0
Loading
/content/journal/jgv/10.1099/vir.0.83523-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error